Redeye thinks the underlying reality of Nepa is improving - with strong sequential ARR growth and fi...
Redeye thinks the Q2 report was good, especially from Investment Management.
Redeye saw sales that were considerably lower than our expectations.
We expect Q2 to be solid, with revenues of SEK 63m FCF guidance should be reiterated.
Redeye saw a Q2 report that was slightly weaker on the top line, with higher costs, making for a low...
Redeye provides an update post Embracers Q1 2023/24 results.
Lower demand continued to affect sales in Q2e Expect FY'23 sales at low end of guidance Fair value r...
On August 18th, Fluicell published the company’s quarterly report for Q2-23.
CoinShares International (CS) delivered another solid set of quarterly results, with Q223 EBITDA of ...
Danderyd (170 units) started in early July Two recent acqusitions and one divestment Q2e GP to incre...
Ecoclime redovisade intäkter i kv2 2023 som var 34 procent högre än vår prognos.
Julisiffror imponerar Omsättningen i kvartalet uppgick till 21 mkr, vilket var något starkare än vad...
Växer starkt med Europa i förarsätet Arcoma redovisar omsättning om 38 mkr (31 mkr) motsvarande en t...
Lägre omsättning, men kraftigt förbättrad lönsamhet Nettoomsättningen minskade med 3% jämfört samma ...
Visar styrka i Q2 och ny guidning Omsättningen för kvartalet uppgick till EUR 17,6m, vilket motsvara...
Redeye’s view on the case remains intact and we have only made minor changes to our forecasts follow...
Trots tuffa jämförelsesiffror och ofördelaktiga kalendereffekter växer DevPort 5% i kvartalet.
Carlsquare Equity Research sammanfattar sina första intryck av InCoax kv2 2023-rapport som presenter...
The FDA feedback later this year will be very important.
Redeye comments on Imint's Q2 2023 report, which had better sales numbers than expected, while profi...
